Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Analyst Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
$504.24
▲(12.26% Upside)
| Highest Price Target$583.00 | Average Price Target$504.24 | Lowest Price Target$370.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
$395→$479
Hold
6.64%
Upside
Reiterated
11/11/25
Piper Sandler
$489
Buy
8.87%
Upside
Reiterated
11/10/25
Morgan Stanley
$495
Hold
10.21%
Upside
Reiterated
11/07/25
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)We analyzed Symphony monthly Amvuttra script data for the month of October, implying growth of 12% m/ m (vs. September; Exhibit 1 ). We note this compares to 5% m/m growth in September suggesting continued strong trends. Additionally scripts grew 38% in October vs. July, the first months of Q4 and Q3, respectively. As a reminder (note here), Alnylam guided to 4Q25 TTR revenue (WW AMvuttra + $897M (midpoint: $872M) which implies sequential growth of +17-24% q/q (midpoint: +20%). Early 4Q25 script trends indicate Amvuttra volume growth in the US remains strong.
H.C. Wainwright
$570
Buy
26.90%
Upside
Reiterated
11/04/25
Evercore ISI
$515
Buy
14.66%
Upside
Reiterated
10/31/25
Truist Financial
―
Buy
―
Reiterated
10/31/25
Oppenheimer
$490→$500
Buy
11.32%
Upside
Reiterated
10/31/25
Barclays
$460→$527
Buy
17.33%
Upside
Reiterated
10/31/25
TD Cowen
$482
Buy
7.31%
Upside
Reiterated
10/30/25
William Blair
―
Buy
―
Reiterated
10/30/25
Alnylam Pharma: Strong Sales Growth and Financial Performance Justify Buy RatingWe believe this is due to lofty investor expectations heading into the print for Amvuttra sales to exceed $695 million to $700 million (Amvuttra sales were $685.3 million for the quarter). GAAP net income of $251.1 million ($1.84/share) was above our estimated income of $224.1 million ($1.71/share) and consensus income of $46 million ($0.57/share). We provide consolidated variance from our estimates in exhibit 1 of the full note. Guidance: Given the strong TTR franchise revenues, Alnylam raised total net product revenues to $2.95 billion to $3.05 billion for 2025, from $2.65 billion to $2.80 billion previously, representing an increase of $275 million, or a 10% increase at the midpoint. TTR franchise net revenue guidance was raised to $2.475 billion to $2.525 billion, from $2.175 billion to $2.275 billion previously.
Needham
$478→$520
Buy
15.77%
Upside
Reiterated
10/30/25
Alnylam Pharma's Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal ConcernsWe await more visibility on the issue, but for now it appears to be more of a near-term headline risk. That said, we are highly encouraged by the revenue growth and the positive TTR franchise outlook and are raising our estimates and PT to $520 (was $478). Disclaimers JOSEPH STRINGER, PH.D.
Jefferies
$550→$549
Buy
22.23%
Upside
Reiterated
10/30/25
Chardan Capital
$475
Buy
5.75%
Upside
Reiterated
10/30/25
Bank of America Securities
$526→$530
Buy
18.00%
Upside
Reiterated
10/30/25
RBC Capital
$500
Buy
11.32%
Upside
Reiterated
10/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
$395→$479
Hold
6.64%
Upside
Reiterated
11/11/25
Piper Sandler
$489
Buy
8.87%
Upside
Reiterated
11/10/25
Morgan Stanley
$495
Hold
10.21%
Upside
Reiterated
11/07/25
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alnylam Pharma (NASDAQ: ALNY) and Insulet (NASDAQ: PODD)We analyzed Symphony monthly Amvuttra script data for the month of October, implying growth of 12% m/ m (vs. September; Exhibit 1 ). We note this compares to 5% m/m growth in September suggesting continued strong trends. Additionally scripts grew 38% in October vs. July, the first months of Q4 and Q3, respectively. As a reminder (note here), Alnylam guided to 4Q25 TTR revenue (WW AMvuttra + $897M (midpoint: $872M) which implies sequential growth of +17-24% q/q (midpoint: +20%). Early 4Q25 script trends indicate Amvuttra volume growth in the US remains strong.
H.C. Wainwright
$570
Buy
26.90%
Upside
Reiterated
11/04/25
Evercore ISI
$515
Buy
14.66%
Upside
Reiterated
10/31/25
Truist Financial
―
Buy
―
Reiterated
10/31/25
Oppenheimer
$490→$500
Buy
11.32%
Upside
Reiterated
10/31/25
Barclays
$460→$527
Buy
17.33%
Upside
Reiterated
10/31/25
TD Cowen
$482
Buy
7.31%
Upside
Reiterated
10/30/25
William Blair
―
Buy
―
Reiterated
10/30/25
Alnylam Pharma: Strong Sales Growth and Financial Performance Justify Buy RatingWe believe this is due to lofty investor expectations heading into the print for Amvuttra sales to exceed $695 million to $700 million (Amvuttra sales were $685.3 million for the quarter). GAAP net income of $251.1 million ($1.84/share) was above our estimated income of $224.1 million ($1.71/share) and consensus income of $46 million ($0.57/share). We provide consolidated variance from our estimates in exhibit 1 of the full note. Guidance: Given the strong TTR franchise revenues, Alnylam raised total net product revenues to $2.95 billion to $3.05 billion for 2025, from $2.65 billion to $2.80 billion previously, representing an increase of $275 million, or a 10% increase at the midpoint. TTR franchise net revenue guidance was raised to $2.475 billion to $2.525 billion, from $2.175 billion to $2.275 billion previously.
Needham
$478→$520
Buy
15.77%
Upside
Reiterated
10/30/25
Alnylam Pharma's Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal ConcernsWe await more visibility on the issue, but for now it appears to be more of a near-term headline risk. That said, we are highly encouraged by the revenue growth and the positive TTR franchise outlook and are raising our estimates and PT to $520 (was $478). Disclaimers JOSEPH STRINGER, PH.D.
Jefferies
$550→$549
Buy
22.23%
Upside
Reiterated
10/30/25
Chardan Capital
$475
Buy
5.75%
Upside
Reiterated
10/30/25
Bank of America Securities
$526→$530
Buy
18.00%
Upside
Reiterated
10/30/25
RBC Capital
$500
Buy
11.32%
Upside
Reiterated
10/30/25
Best Analysts Covering Alnylam Pharma
1 Month
xxx
Success Rate
21/36 ratings generated profit
Average Return
+1.15%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +1.15% per trade.
3 Months
xxx
Success Rate
22/31 ratings generated profit
Average Return
+10.12%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +10.12% per trade.
1 Year
Success Rate
28/31 ratings generated profit
Average Return
+42.14%
reiterated a buy rating 18 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 90.32% of your transactions generating a profit, with an average return of +42.14% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
Average Return
+94.50%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +94.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALNY Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
3
1
0
0
0
Buy
41
41
48
51
34
Hold
13
15
15
15
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
57
63
66
45
Each month's total comprises the sum of three months' worth of ratings.
ALNY Financial Forecast
ALNY Stock Forecast FAQ
What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 504.24.
What is ALNY’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 12.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALNY a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s price target?
The average price target for Alnylam Pharmaceuticals is 504.24. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $583.00 ,the lowest forecast is $370.00. The average price target represents 12.26% Increase from the current price of $449.16.
The highest analyst price target is $583.00 ,the lowest forecast is $370.00. The average price target represents 12.26% Increase from the current price of $449.16.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of ALNY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.